Investors might want to bet on Marinus Pharmaceuticals (MRNS) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Sinc ...

Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.55%. A quarter ago, it was expected that this epilepsy drug developer would post a loss of $0.59 per share when it actually produced a loss of $0.60, delivering a surprise of -1.69%.Over the last four quarters, t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-36576 MARINUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 20-0198082 (State ...

Exhibit 99.1 Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results ● ZTALMY® (ganaxolone) Q3 2024 net product revenue of $8.5 million representing growth of 56% versus Q3 2023 ● Narrowing full year 2024 ZTALMY net product revenue guidance to $33 to $34 million ● Reported results from Phase 3 TrustTSC trial and commenced process to explore strategic alternatives ● Marinus continues to support the commercial growth of ZTALMY; further ganaxolone clinical development ...

Marinus Pharmaceuticals NASDAQ: MRNS is a micro-cap pharmaceutical stock with multiple Wall Street analysts seeing significant upside. Both Oppenheimer and Cantor Fitzgerald recently issued or reiterated massive price targets for the company. Oppenheimer's $6 target signals that shares could rise 241% from their current $1.76 level, which is over triple-bagger potential. Marinus Pharmaceuticals Today MRNS Marinus Pharmaceuticals $1.75 -0.01 (-0.57%) 52-Week Range $1.05 ▼ $11.26 Price Target $8.83 Add to Wat ...

Corporate Presentation August 2024 Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "ma ...

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Sonya Weigle - Chief People and Investor Relations Officer Scott Braunstein - Chairman and Chief Executive Officer Lisa Lejuwaan - Senior Vice President and Business Unit Lead, Rare Genetic Epilepsy Joseph Hulihan - Chief Medical Officer Steven Pfanstiel - Chief Financial Officer and Chief Operating Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Joseph Thome - ...

Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -1.69%. A quarter ago, it was expected that this epilepsy drug developer would post a loss of $0.68 per share when it actually produced a loss of $0.68, delivering no surprise. Over the last four quarters, the com ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-36576 MARINUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 20-0198082 (State or o ...

Exhibit 99.1 Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results ● ZTALMY® (ganaxolone) Q2 2024 net product revenue of $8.0 million representing strong growth of 87% versus Q2 2023 ● On track to achieve full year 2024 ZTALMY net product revenue guidance of between $33 and $35 million ● Completed enrollment in the Phase 3 TrustTSC trial of oral ganaxolone in tuberous sclerosis complex (TSC) with topline data expected in the first half of Q4 2024 ● Expanded ZTALM ...